Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

  title={Lessons from Anti-Amyloid-$\beta$ Immunotherapies in Alzheimer Disease: Aiming at a Moving Target},
  author={Youmei Wang and Tao Yan and Honghui Lu and Weiming Yin and Bin Lin and Weibin Fan and Xiaoli Zhang and Pedro Fernandez-Funez},
  journal={Neurodegenerative Diseases},
  pages={242 - 250}
Background: Available drugs for the global Alzheimer disease (AD) epidemic only treat the symptoms without modifying disease progression. Accumulating evidence supports amyloid-β42 (Aβ42)as the key triggering agent in AD, making it the ideal target for disease-modifying therapies. Preclinical studies provided extensive support for passive Aβ42 immunotherapy, leading to human clinical trials with different antibodies. Objective: Examine the status of clinical trials for passive immunotherapy… 
Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform
A satisfactory validation of the data from multiple preclinical and clinical studies was followed by an attempt to predict the results of combinatorial treatment with targeted immunotherapy and activation of autophagy using rapamycin, predicted to yield better efficacy than immunotherapy alone.
Immunotherapy in Parkinson’s disease: Current status and future directions
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies.
The amyloid cascade hypothesis, according to which the self-assembly of amyloid-β peptide (Aβ) is a causative process in Alzheimer's disease, has driven many therapeutic efforts for the past 20
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions
This work summarizes immunotherapeutic approaches that were tested in pre-clinical or clinical studies in the last two decades in an attempt to treat Parkinson’s disease and suggests antibodies targeting extra- or intracellular alpha-synuclein could be efficient in limiting the aggregation and transmission.
Anti-Aβ single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer’s disease
Olfactory classical conditioning is used to observe that both scFv antibodies significantly improve memory performance in flies expressing Aβ42 in the mushroom body neurons, which are intimately involved in the coding and storage of olfactory memories.
Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
It is shown by using immunohistochemistry that in unimmunized AD patients Aβ43 is a frequent constituent of plaques, similar to Aβ42 (3.9% immunostained area), and that A β43 is cleared from plaques after Aβ immunotherapy,Similar to A β42 and Aβ40.
Alzheimer’s Disease, Oligomers, and Inflammation
According to the precision medicine principles, innovative therapeutic approaches to AD are proposed based on the patient’s inflammatory profile/state, with the earlier intervention and a multifactor approach considered essential to improve the chances of effective therapy in AD.
Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model
Results suggest that GW-23B7, an anti-β-sheet conformational mAb humanized for clinical trials, may be an effective therapeutic agent for human AD.


Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
These primary and secondary prevention trials will definitely test the Aβ cascade hypothesis of AD, and new passive anti-Aβ immunotherapies have been developed and are under clinical testing.
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Both active and passive anti-A&bgr; immunotherapies were shown to clear brain A&b gr; deposits, and two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab and solanezumab were disappointing.
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Two ongoing Phase III trials of gantenerumab in patients with prodromal or mild dementia due to AD will determine if any reduction in brain Aβ levels will translate into clinical benefits and verify the utility of anti-Aβ monoclonal antibodies as prevention therapy.
Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
  • N. Relkin
  • Biology, Medicine
    Journal of Clinical Immunology
  • 2014
Findings suggest that naturally occurring human anti-amyloid antibodies may play a physiologic role in the clearance of aggregated amyloid proteins in Alzheimer's disease.
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
The first clinical study with BAN2401, a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils, found it well-tolerated across all doses and guided the selection of dose and dose regimens in the ongoing phase 2b study.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
This phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interrupted because of meningoencephalitis provides an indication that Aβ immunotherapy may be useful in Alzheimer disease.
Drug treatments in Alzheimer's disease.
Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials and results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution.
Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies
A new methodology for future treatment research in Alzheimer’s disease considering early intervention with more focus on cognitive decline as a screening tool, more sophisticated exclusion criteria with more reliance on biomarkers, and a longer study duration with periodic assessment of cognition.